# Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support

> **NCT03922451** · — · TERMINATED · sponsor: **Boston Children's Hospital** · enrollment: 4 (actual)

## Conditions studied

- Drug Effect

## Interventions

- **DRUG:** piperacillin-tazobactam
- **DRUG:** Cefazolin

## Key facts

- **NCT ID:** NCT03922451
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-27
- **Primary completion:** 2020-04-01
- **Final completion:** 2022-02-28
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** COVID-19 - study and recruitment not feasible
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03922451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03922451, "Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT03922451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*